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Figure S1. Quantitative RT-PCR analysis of PMM-2 expression in pmm-2 F125L (F119L) 
homozygote mutant worms compared to the heterozygous pmm-2 deletion mutant and a wildtype 
reference strain (N2). ∆Cq values were calculated by subtracting the reference transcript (cdc-42) 
cycle quantification (Cq) number from that of the target transcript (pmm-2). From left to right, 
∆Cq values for N2, pmm-2 F125L/F125L homozygote mutant 
(COP1626) and pmm-2 heterozygous mutant (VC3054) are displayed. Each bar consists of data 
from three biological replicates. Error bars are standard error of mean ∆Cq across three replicates  
∆Cq values are not significantly different from wildtype indicating that both homozygous and 
heterozygous mutants produce the same level of pmm-2 transcript as N2. 
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Figure S2. Box and whisker plots of z scores of positive and negative control wells from a 
representative replicate of the Microsource Spectrum drug repurposing library screen. Negative 
controls have Z score values of 0, whereas Z score values of positive controls are > 2. 
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Figure S3. Chemical structures of yeast repurposing candidates from Lao et al, 2019 (1) 2’-2’-
bisepigallocatechin digallate (2) suramin (3) alpha-cyano-4-hydroxycinnamic acid, and the 
chemical structure of the aldose reductase inhibitor epalrestat (4). Notice the shared carboxylic 
moiety of 3 and 4. 
Disease Models & Mechanisms: doi:10.1242/dmm.040584: Supplementary information
D
is
ea
se
 M
o
de
ls
 &
 M
ec
ha
ni
sm
s 
• 
S
up
pl
em
en
ta
ry
 in
fo
rm
at
io
n
Figure S4. PMM2 enzymatic activity assay of R141/F119L PMM2-CDG patient fibroblasts. 
Supplemented samples were treated with 10µM epalrestat for 24 hour. Error bars in the bar 
graphs indicate standard error. 
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Figure S5. Quantitative RT-PCR analysis of PMM-2 and ER stress marker expression in 
pmm-2 F125L/F125L homozygote mutant worms. 
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Figure S6. Dose-response curves of four worm PMM2 repurposing hits in a Keap1-NRF2 
reporter activation assay in human cells generated by DiscoverX. (A) pyrogallin. (B) fisetin. (C) 
rhamnetin. D) purpurogallin-4-carboxylic acid.
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Figure S7. Growth of three yeast PMM2-CDG models (pACT1-F126L/R148H; pSEC53-
V238M/R148H; pSEC53-F126L/R148H) in the presence of the 20 worm repurposing 
candidates at 10µM, 25µM and 50µM. Compounds tested from left to right: pyrogallin, amidol, 
baicalein, purpurogallin-4-carboxylic acid, gossypetin, quercetin tetramethylether, 3-
methoxycatechol, rhamnetin, theaflavin monogallate, hieracin (tricetin), epicatechin 
monogallate, 3,4-didesmethyl-5-deshydroxy-3-ethoxyschleroin, 2,3,4-trihydroxy-4-
methoxybenzophenone, koparin, fisetin, edaravone, ellagic acid, levodopa, dobutamine and 
ethylnorepinephrine. Asterisks indicate compounds that have either positive or negative effects 
on growth. 
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Figure S8. Chemical structures of 10 commercially available aldose reductase inhibitors tested 
in PMM2-CDG R141H/F119L fibroblasts.  
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